CN1777437A - 生物活性天然生物基质组合物 - Google Patents
生物活性天然生物基质组合物 Download PDFInfo
- Publication number
- CN1777437A CN1777437A CNA200480010779XA CN200480010779A CN1777437A CN 1777437 A CN1777437 A CN 1777437A CN A200480010779X A CNA200480010779X A CN A200480010779XA CN 200480010779 A CN200480010779 A CN 200480010779A CN 1777437 A CN1777437 A CN 1777437A
- Authority
- CN
- China
- Prior art keywords
- exists
- weight
- cell
- scope
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 121
- 230000012010 growth Effects 0.000 claims abstract description 92
- 108010035532 Collagen Proteins 0.000 claims abstract description 73
- 102000008186 Collagen Human genes 0.000 claims abstract description 73
- 229920001436 collagen Polymers 0.000 claims abstract description 66
- 108010085895 Laminin Proteins 0.000 claims abstract description 31
- 102000007547 Laminin Human genes 0.000 claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 30
- 210000001691 amnion Anatomy 0.000 claims abstract description 27
- 108010008125 Tenascin Proteins 0.000 claims abstract description 26
- 102000007000 Tenascin Human genes 0.000 claims abstract description 26
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 23
- 102000016359 Fibronectins Human genes 0.000 claims abstract description 23
- 102000035195 Peptidases Human genes 0.000 claims abstract description 10
- 108091005804 Peptidases Proteins 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 140
- 238000000034 method Methods 0.000 claims description 113
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 69
- 102000013275 Somatomedins Human genes 0.000 claims description 69
- 239000011159 matrix material Substances 0.000 claims description 68
- 239000000758 substrate Substances 0.000 claims description 55
- 208000020431 spinal cord injury Diseases 0.000 claims description 50
- 210000001519 tissue Anatomy 0.000 claims description 37
- 230000033115 angiogenesis Effects 0.000 claims description 36
- 102100034613 Annexin A2 Human genes 0.000 claims description 33
- 108090000668 Annexin A2 Proteins 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 33
- 230000001537 neural effect Effects 0.000 claims description 33
- 230000004069 differentiation Effects 0.000 claims description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 27
- 210000003725 endotheliocyte Anatomy 0.000 claims description 26
- 108010088225 Nestin Proteins 0.000 claims description 25
- 102000008730 Nestin Human genes 0.000 claims description 25
- 210000005055 nestin Anatomy 0.000 claims description 25
- 238000011534 incubation Methods 0.000 claims description 24
- 101150021185 FGF gene Proteins 0.000 claims description 22
- 101710145505 Fiber protein Proteins 0.000 claims description 22
- 238000004113 cell culture Methods 0.000 claims description 18
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 15
- 210000002889 endothelial cell Anatomy 0.000 claims description 15
- 210000000130 stem cell Anatomy 0.000 claims description 15
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 14
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 14
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 210000002569 neuron Anatomy 0.000 claims description 12
- 230000035790 physiological processes and functions Effects 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 11
- 230000001413 cellular effect Effects 0.000 claims description 11
- 239000000725 suspension Substances 0.000 claims description 11
- 230000004071 biological effect Effects 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 210000005155 neural progenitor cell Anatomy 0.000 claims description 10
- 210000003606 umbilical vein Anatomy 0.000 claims description 10
- 208000037273 Pathologic Processes Diseases 0.000 claims description 9
- 230000024245 cell differentiation Effects 0.000 claims description 9
- 230000009054 pathological process Effects 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 9
- 239000006143 cell culture medium Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 7
- 230000020411 cell activation Effects 0.000 claims description 7
- 210000002826 placenta Anatomy 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 230000012292 cell migration Effects 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 210000005036 nerve Anatomy 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 6
- 108010073385 Fibrin Proteins 0.000 claims description 5
- 102000009123 Fibrin Human genes 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 5
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 5
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 239000000385 dialysis solution Substances 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- 230000008467 tissue growth Effects 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 230000010072 bone remodeling Effects 0.000 claims description 4
- 210000003494 hepatocyte Anatomy 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 230000033458 reproduction Effects 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 230000004218 vascular function Effects 0.000 claims description 4
- 102000029816 Collagenase Human genes 0.000 claims description 3
- 108060005980 Collagenase Proteins 0.000 claims description 3
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 3
- 229920002971 Heparan sulfate Polymers 0.000 claims description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- -1 PDGF Proteins 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 229960002424 collagenase Drugs 0.000 claims description 3
- 210000001178 neural stem cell Anatomy 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 230000025366 tissue development Effects 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 102100034612 Annexin A4 Human genes 0.000 claims description 2
- 108090000669 Annexin A4 Proteins 0.000 claims description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 2
- 102000004264 Osteopontin Human genes 0.000 claims description 2
- 108010081689 Osteopontin Proteins 0.000 claims description 2
- 102100035140 Vitronectin Human genes 0.000 claims description 2
- 108010031318 Vitronectin Proteins 0.000 claims description 2
- 239000000908 ammonium hydroxide Substances 0.000 claims description 2
- 239000003966 growth inhibitor Substances 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 150000002894 organic compounds Chemical class 0.000 claims 8
- 230000000926 neurological effect Effects 0.000 claims 3
- 239000011049 pearl Substances 0.000 claims 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims 2
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 2
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 2
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 claims 2
- 210000002919 epithelial cell Anatomy 0.000 claims 2
- 238000011010 flushing procedure Methods 0.000 claims 2
- 230000014511 neuron projection development Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 102100034278 Annexin A6 Human genes 0.000 claims 1
- 108090000656 Annexin A6 Proteins 0.000 claims 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims 1
- 101001082397 Human adenovirus B serotype 3 Hexon-associated protein Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 101710188314 Protein V Proteins 0.000 claims 1
- 101000918244 Pseudoalteromonas phage PM2 Peptidoglycan hydrolase P7 Proteins 0.000 claims 1
- 101000584831 Pseudoalteromonas phage PM2 Protein P6 Proteins 0.000 claims 1
- 101001120093 Pseudoalteromonas phage PM2 Protein P8 Proteins 0.000 claims 1
- 229910021529 ammonia Inorganic materials 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- 238000004140 cleaning Methods 0.000 claims 1
- 210000002744 extracellular matrix Anatomy 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 210000002469 basement membrane Anatomy 0.000 abstract description 38
- 239000000021 stimulant Substances 0.000 abstract description 13
- 239000003102 growth factor Substances 0.000 abstract description 10
- 238000000338 in vitro Methods 0.000 abstract description 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 229920001184 polypeptide Polymers 0.000 abstract description 7
- 102000012422 Collagen Type I Human genes 0.000 abstract description 6
- 108010022452 Collagen Type I Proteins 0.000 abstract description 6
- 108010067787 Proteoglycans Proteins 0.000 abstract description 3
- 102000016611 Proteoglycans Human genes 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 230000001575 pathological effect Effects 0.000 abstract description 2
- 230000008093 supporting effect Effects 0.000 abstract description 2
- 102100037369 Nidogen-1 Human genes 0.000 abstract 1
- 108010008217 nidogen Proteins 0.000 abstract 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 abstract 1
- 108010082117 matrigel Proteins 0.000 description 44
- 238000002360 preparation method Methods 0.000 description 38
- 241001465754 Metazoa Species 0.000 description 33
- 230000008569 process Effects 0.000 description 24
- 239000001963 growth medium Substances 0.000 description 22
- 238000011160 research Methods 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 241000700159 Rattus Species 0.000 description 20
- 102400001368 Epidermal growth factor Human genes 0.000 description 16
- 101800003838 Epidermal growth factor Proteins 0.000 description 16
- 229940116977 epidermal growth factor Drugs 0.000 description 16
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 230000010261 cell growth Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- 238000013508 migration Methods 0.000 description 13
- 230000006378 damage Effects 0.000 description 12
- 239000007943 implant Substances 0.000 description 12
- 230000005012 migration Effects 0.000 description 12
- 230000004936 stimulating effect Effects 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 210000004748 cultured cell Anatomy 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 238000011069 regeneration method Methods 0.000 description 8
- 230000017423 tissue regeneration Effects 0.000 description 8
- 101150079463 NBL1 gene Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 101150118520 dan gene Proteins 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000035479 physiological effects, processes and functions Effects 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 230000000704 physical effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 239000002870 angiogenesis inducing agent Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000010413 mother solution Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 229920001222 biopolymer Polymers 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003636 conditioned culture medium Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000003900 neurotrophic factor Substances 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000000278 spinal cord Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 231100000588 tumorigenic Toxicity 0.000 description 4
- 230000000381 tumorigenic effect Effects 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000007072 Nerve Growth Factors Human genes 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000002491 angiogenic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 239000000017 hydrogel Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012913 medium supplement Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 2
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229920005479 Lucite® Polymers 0.000 description 2
- 102400000058 Neuregulin-1 Human genes 0.000 description 2
- 108090000556 Neuregulin-1 Proteins 0.000 description 2
- 102000004230 Neurotrophin 3 Human genes 0.000 description 2
- 108090000742 Neurotrophin 3 Proteins 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000008619 cell matrix interaction Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000006576 neuronal survival Effects 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000000399 optical microscopy Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SRSXVRUMXPCNAJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3',6'-diacetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound C=1C(OC(=O)C)=CC=C2C=1OC1=CC(OC(C)=O)=CC=C1C2(C1=CC=2)OC(=O)C1=CC=2C(=O)ON1C(=O)CCC1=O SRSXVRUMXPCNAJ-UHFFFAOYSA-N 0.000 description 1
- YIYCUMYWGOOSNU-FMZZOXHWSA-N 2-[[(2s)-1-[(2s,3s)-2-[[(2s,3r)-2-[[2-[[(2s)-2-amino-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O YIYCUMYWGOOSNU-FMZZOXHWSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 208000025940 Back injury Diseases 0.000 description 1
- 108010085511 Biomatrix preparation Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 208000009331 Experimental Sarcoma Diseases 0.000 description 1
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940039412 ketalar Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 230000033667 organ regeneration Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000000247 postprecipitation Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 210000002804 pyramidal tract Anatomy 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 238000007805 zymography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
- A61L27/3675—Nerve tissue, e.g. brain, spinal cord, nerves, dura mater
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/383—Nerve cells, e.g. dendritic cells, Schwann cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3878—Nerve tissue, brain, spinal cord, nerves, dura mater
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N2533/92—Amnion; Decellularised dermis or mucosa
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Dispersion Chemistry (AREA)
Abstract
Description
HuBiogelTM1 | Matrigel2 | |
总蛋白质(mg/ml) | 5-8 | 10-15 |
层粘连蛋白 | 260+/-24 | 810 |
胶原蛋白I | 478+/-32 | n.s. |
胶原蛋白IV | 312+/-18 | 450 |
巢蛋白 | 164+/-20 | 120 |
腱生蛋白 | 68+/-6 | n.s. |
纤连蛋白 | 18+/-4 | n.s. |
蛋白聚糖 | 14+/-6 | 25 |
EGF | 无 | 0.7ng |
TGF-B | 无 | 3ng |
BFGF | 无 | 0.2pg |
PDGF | 无 | 12pg |
VEGF | 无 | 16ng |
胶原蛋白酶 | 无 | 可检测到 |
性能 | HuBiogelTM | Matrigel | Col./Fib.凝胶 |
来源/起源: | 人胎盘(羊膜) | 小鼠EHS肿瘤 | 大鼠或小鼠组织 |
物理形式: | 半凝胶,天然ECM | 液体/凝胶重构的ECM | 液体/凝胶纯化的ECM |
凝胶化/包衣: | 均匀,有弹性 | 不均匀或渗漏 | 不均匀或渗漏 |
处理: | 稳定凝胶(4℃到37℃) | 温度敏感 | 温度敏感 |
ECM-环境: | 确定的,生理的 | 肿瘤发生的和血管生成的 | 人工的 |
主要ECM组分: | 胶原蛋白I和IV、层粘连蛋白、巢蛋白、腱生蛋白、纤连蛋白、蛋白聚糖 | 层粘连蛋白、胶原蛋白IV、巢蛋白、蛋白聚糖 | 天然或变性的ECM蛋白质 |
生长因子: | 无,不可检测 | TGF、EGF、PDGF、IGF、FGF | - |
蛋白酶: | 无,不可检测 | 胶原蛋白酶活性 | - |
功能优点: | 正常细胞生长,定向或受控的信号环境 | 不受控的细胞活化、分化 | 需要诱导或其他修饰 |
HuBiogelTM系统 | 生物聚合物系统 | 纯化的基质系统 | |
来源/环境 | 人,生理的ECM组成 | 合成的移植物人工基质 | 动物来源的ECM蛋白质或肽 |
当前系统 | 新的、确定的生物基质系统 | PLA、PLGA、水凝胶、Neurogel | 血纤蛋白、胶原蛋白I、藻酸盐、层粘连蛋白 |
结构性能 | 半凝胶和可注射的制剂 | 固体植入物,不可注射 | 凝胶植入物,不可注射 |
生物学性能 | 受控的细胞生长、分化和组织 | 需要生长通道、差的生物相容性和不受控的环境 | 形成血栓或者疤痕形成效果、弱的细胞存活和组织 |
Claims (103)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44930303P | 2003-02-21 | 2003-02-21 | |
US60/449,303 | 2003-02-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1777437A true CN1777437A (zh) | 2006-05-24 |
CN100412188C CN100412188C (zh) | 2008-08-20 |
Family
ID=32927509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200480010779XA Expired - Lifetime CN100412188C (zh) | 2003-02-21 | 2004-02-23 | 生物活性天然生物基质组合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7727550B2 (zh) |
EP (1) | EP1617854B1 (zh) |
CN (1) | CN100412188C (zh) |
GB (1) | GB2414990B (zh) |
HK (1) | HK1089655A1 (zh) |
WO (1) | WO2004076631A2 (zh) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103491898A (zh) * | 2010-07-02 | 2014-01-01 | 北卡罗来纳-查佩尔山大学 | 用于工业规模分散的生物基质支架 |
CN102246045B (zh) * | 2008-10-16 | 2014-04-02 | 希托尼克斯公司 | 用于检测和治疗脊柱和关节疼痛的生物标志物和方法 |
CN102272288B (zh) * | 2009-01-08 | 2015-03-11 | 株式会社日立制作所 | 动物肝细胞的培养方法 |
CN104704108A (zh) * | 2012-10-05 | 2015-06-10 | 日本写真印刷株式会社 | 细胞培养构件和细胞培养方法 |
CN105727372A (zh) * | 2016-02-25 | 2016-07-06 | 烟台隽秀生物科技有限公司 | 一种温敏性宫腔修复凝胶及其制备方法 |
CN107635567A (zh) * | 2015-04-17 | 2018-01-26 | 加利福利亚大学董事会 | 用于细胞输送、细胞培养和炎症预防的脱细胞化的人羊膜 |
CN109270202A (zh) * | 2018-10-11 | 2019-01-25 | 中国药科大学 | 一种动物肝脏内乙酰辅酶a的液质联用测定方法 |
CN116948014A (zh) * | 2023-07-18 | 2023-10-27 | 山西锦波生物医药股份有限公司 | 生物合成人体结构性材料vi型胶原蛋白的方法 |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005121316A1 (en) * | 2004-06-11 | 2005-12-22 | Bernard O'brien Institute Of Microsurgery | Tissue material and muscle derived matrix |
AU2006254703B2 (en) * | 2005-05-30 | 2010-12-23 | Commonwealth Scientific And Industrial Research Organisation | Preparation and use of basement membrane particles |
ATE469209T1 (de) * | 2005-05-30 | 2010-06-15 | Commw Scient Ind Res Org | Herstellung und verwendung von basalmembranpartikeln |
CN101501185A (zh) * | 2006-06-09 | 2009-08-05 | 人类起源公司 | 胎盘巢(placental niche)及其培养干细胞的用途 |
US8372437B2 (en) | 2006-08-17 | 2013-02-12 | Mimedx Group, Inc. | Placental tissue grafts |
KR20210018526A (ko) * | 2006-10-06 | 2021-02-17 | 안트로제네시스 코포레이션 | 천연(텔로펩티드) 태반 콜라겐 조성물 |
JP5458279B2 (ja) * | 2007-04-17 | 2014-04-02 | 学校法人北里研究所 | 可溶化羊膜組成物及びその用途 |
JP5234535B2 (ja) * | 2007-06-25 | 2013-07-10 | 株式会社ニデック | 哺乳動物未成熟卵子の体外成熟培養用添加剤及びそれを用いた成熟卵子の作出方法 |
SI2211851T1 (sl) * | 2007-10-09 | 2014-11-28 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Laminin-1 za uporabo pri izboljĺ anju regeneracije miĺ ice po poĺ kodbi ali za izboljĺ anje celjenja ran ob sistemski administraciji |
US9480549B2 (en) | 2008-04-25 | 2016-11-01 | Allosource | Multi-layer tissue patches |
US9358320B2 (en) | 2008-04-25 | 2016-06-07 | Allosource | Multi-layer tissue patches |
US20110123497A1 (en) * | 2009-11-20 | 2011-05-26 | Fina Biotech, S.L.U. | Graft composition for neural tissue regeneration, method of production and uses thereof |
US20140255507A9 (en) * | 2010-10-14 | 2014-09-11 | The Regents Of The University Of California | Method for promoting the synthesis of collagen and proteoglycan in chondrocytes |
WO2012118799A2 (en) | 2011-02-28 | 2012-09-07 | President And Fellows Of Harvard College | Cell culture system |
US8932805B1 (en) | 2011-10-31 | 2015-01-13 | BioDlogics, LLC | Birth tissue material and method of preparation |
US9162011B2 (en) | 2011-12-19 | 2015-10-20 | Allosource | Flowable matrix compositions and methods |
CN102631708B (zh) * | 2012-05-17 | 2014-01-15 | 重庆市畜牧科学院 | 盆底补片复合生物材料的制备方法及其产品 |
US9566310B2 (en) | 2012-09-10 | 2017-02-14 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno | Methods of treating muscular dystrophy |
US11077229B1 (en) | 2013-03-08 | 2021-08-03 | BioDlogics, LLC | Implant coating composition and method of use |
US10016459B1 (en) | 2013-03-13 | 2018-07-10 | BioDlogics, LLC | Platelet-rich plasma derived from human umbilical cord blood |
EP2968646B1 (en) | 2013-03-13 | 2019-05-29 | AlloSource | Fascia fibrous compositions and methods for their use and manufacture |
EP2970882B1 (en) | 2013-03-15 | 2018-11-28 | AlloSource | Cell repopulated collagen matrix for soft tissue repair and regeneration |
WO2014144606A2 (en) | 2013-03-15 | 2014-09-18 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Methods of treating muscular dystrophy |
US9795639B1 (en) | 2013-03-16 | 2017-10-24 | BioDlogics, LLC | Methods for the treatment of erectile dysfunction by human birth tissue material compostion |
US9993506B1 (en) | 2013-03-16 | 2018-06-12 | BioDlogics, Inc. | Methods for the treatment of degenerative disc diseases by human birth tissue material composition |
US10555897B1 (en) | 2013-03-16 | 2020-02-11 | Brahm Holdings Llc | Cosmetic composition and methods of treatment |
US10039792B1 (en) | 2013-03-16 | 2018-08-07 | Brahm Holdings, Llc | Methods for the treatment of inflammation and pain using human birth tissue material composition |
CN103705979B (zh) * | 2013-09-18 | 2016-10-05 | 中国人民解放军海军总医院 | 用于神经修复的功能组织工程材料及其制备与用途 |
KR101832203B1 (ko) | 2013-12-06 | 2018-02-27 | 알로소스 | 조직의 시트를 건조하는 방법 |
US10201573B1 (en) | 2014-10-27 | 2019-02-12 | Brahm Holdings, Llc | Human birth tissue material composition and methods for the treatment of damage associated with a cerebral vascular accident |
US10265438B1 (en) | 2014-11-03 | 2019-04-23 | BioDlogics, LLC | Methods and compositions for the repair and replacement of connective tissue |
WO2016146893A1 (en) | 2015-03-17 | 2016-09-22 | University Of Oulu | Human tumor based extracellular matrix for cell studies in vitro |
KR102590429B1 (ko) * | 2015-05-29 | 2023-10-16 | 라이프넷 헬스 | 태반-유래 기질 및 이의 제조 방법 및 용도 |
JP7002530B2 (ja) * | 2016-03-29 | 2022-02-04 | エスエムエスバイオテック インコーポレイテッド | 小型運動性幹細胞を使用した組成物および方法 |
KR20180133881A (ko) * | 2016-04-07 | 2018-12-17 | 몰레큘라 레바 디자인 엘엘씨 | 이산 탄소 나노튜브로부터의 줄기 세포, 골, 조직 및 신경 스캐폴딩 |
US12104174B2 (en) | 2016-09-13 | 2024-10-01 | President And Fellows Of Harvard College | Methods relating to intestinal organ-on-a-chip |
US10772986B2 (en) | 2017-01-26 | 2020-09-15 | Allosource | Fascia fibrous compositions and methods for their use and manufacture |
US20210395681A1 (en) * | 2018-10-11 | 2021-12-23 | Ichimaru Pharcos Co., Ltd. | Culture medium for growth of neural stem cells |
JPWO2021206055A1 (zh) * | 2020-04-08 | 2021-10-14 | ||
US12109327B2 (en) * | 2020-08-20 | 2024-10-08 | King Abdullah University Of Science And Technology | Scaffolds from self-assembling tetrapeptides support 3D spreading, osteogenic differentiation and angiogenesis of mesenchymal stem cells |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4829000A (en) * | 1985-08-30 | 1989-05-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Reconstituted basement membrane complex with biological activity |
US5354666A (en) * | 1991-08-01 | 1994-10-11 | Thomas Jefferson University | Mammalian cell line expressing basement membrane proteins |
US5326357A (en) * | 1992-03-18 | 1994-07-05 | Mount Sinai Hospital Corporation | Reconstituted cartridge tissue |
US6152142A (en) * | 1997-02-28 | 2000-11-28 | Tseng; Scheffer C. G. | Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries |
US6179872B1 (en) * | 1998-03-17 | 2001-01-30 | Tissue Engineering | Biopolymer matt for use in tissue repair and reconstruction |
US6893812B2 (en) * | 2000-05-30 | 2005-05-17 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Three-dimensional ex vivo angiogenesis system |
CA2388723C (en) * | 2001-06-06 | 2012-10-23 | Becton, Dickinson & Company | Method of providing a substrate with a ready-to-use, uniformly distributed extracellular matrix |
-
2004
- 2004-02-23 GB GB0519272A patent/GB2414990B/en not_active Expired - Lifetime
- 2004-02-23 EP EP04713755.9A patent/EP1617854B1/en not_active Expired - Lifetime
- 2004-02-23 WO PCT/US2004/005255 patent/WO2004076631A2/en active Application Filing
- 2004-02-23 US US10/546,506 patent/US7727550B2/en active Active
- 2004-02-23 CN CNB200480010779XA patent/CN100412188C/zh not_active Expired - Lifetime
-
2006
- 2006-06-14 HK HK06106830A patent/HK1089655A1/xx not_active IP Right Cessation
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102246045B (zh) * | 2008-10-16 | 2014-04-02 | 希托尼克斯公司 | 用于检测和治疗脊柱和关节疼痛的生物标志物和方法 |
CN102272288B (zh) * | 2009-01-08 | 2015-03-11 | 株式会社日立制作所 | 动物肝细胞的培养方法 |
US10640747B2 (en) | 2010-07-02 | 2020-05-05 | The University Of North Carolina At Chapel Hill | Biomatrix scaffolds for industrial scale dispersal |
CN103491898B (zh) * | 2010-07-02 | 2015-11-25 | 北卡罗来纳-查佩尔山大学 | 用于工业规模分散的生物基质支架 |
CN105713868A (zh) * | 2010-07-02 | 2016-06-29 | 北卡罗来纳-查佩尔山大学 | 用于工业规模分散的生物基质支架 |
CN103491898A (zh) * | 2010-07-02 | 2014-01-01 | 北卡罗来纳-查佩尔山大学 | 用于工业规模分散的生物基质支架 |
US9944896B2 (en) | 2010-07-02 | 2018-04-17 | The University Of North Carolina At Chapel Hill | Biomatrix scaffolds for industrial scale dispersal |
US10246678B2 (en) | 2010-07-02 | 2019-04-02 | The University Of North Carolina At Chapel Hill | Biomatrix scaffolds |
CN104704108A (zh) * | 2012-10-05 | 2015-06-10 | 日本写真印刷株式会社 | 细胞培养构件和细胞培养方法 |
CN107635567A (zh) * | 2015-04-17 | 2018-01-26 | 加利福利亚大学董事会 | 用于细胞输送、细胞培养和炎症预防的脱细胞化的人羊膜 |
US11028362B2 (en) | 2015-04-17 | 2021-06-08 | The Regents Of The University Of California | Decellularized human amniotic membrane for cell delivery, cell culture and inflammation prevention |
CN105727372A (zh) * | 2016-02-25 | 2016-07-06 | 烟台隽秀生物科技有限公司 | 一种温敏性宫腔修复凝胶及其制备方法 |
CN109270202A (zh) * | 2018-10-11 | 2019-01-25 | 中国药科大学 | 一种动物肝脏内乙酰辅酶a的液质联用测定方法 |
CN116948014A (zh) * | 2023-07-18 | 2023-10-27 | 山西锦波生物医药股份有限公司 | 生物合成人体结构性材料vi型胶原蛋白的方法 |
CN116948014B (zh) * | 2023-07-18 | 2024-05-10 | 山西锦波生物医药股份有限公司 | 生物合成人体结构性材料vi型胶原蛋白的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100412188C (zh) | 2008-08-20 |
EP1617854A2 (en) | 2006-01-25 |
GB2414990B (en) | 2007-05-23 |
WO2004076631A3 (en) | 2005-05-12 |
EP1617854B1 (en) | 2014-08-06 |
US20070154552A1 (en) | 2007-07-05 |
US7727550B2 (en) | 2010-06-01 |
GB2414990A (en) | 2005-12-14 |
WO2004076631A2 (en) | 2004-09-10 |
GB0519272D0 (en) | 2005-10-26 |
HK1089655A1 (en) | 2006-12-08 |
EP1617854A4 (en) | 2009-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100412188C (zh) | 生物活性天然生物基质组合物 | |
US10675303B2 (en) | Extracellular matrix compositions for the treatment of cancer | |
RU2631488C2 (ru) | Кондиционированная среда и композиции на основе внеклеточного матрикса из клеток, культивированных в гипоксических условиях | |
KR101650957B1 (ko) | 세포외 기질 조성물 | |
Marchini et al. | Synthetic scaffolds for 3D cell cultures and organoids: applications in regenerative medicine | |
JP2017095493A (ja) | 心臓治療のための組成物及び方法 | |
CN101925675A (zh) | 生物工程化组织构建物及其制备和使用方法 | |
WO2014181886A1 (ja) | 粒子状脱細胞化組織を含むハイブリッドゲル | |
KR19990022216A (ko) | 자연적으로 분비되는 세포외 매트릭스 조성물과 그 방법 | |
CN101084026A (zh) | 含有生脂间充质干细胞的聚乙二醇-双丙烯酸酯(pegda)交联的水凝胶 | |
JP2008523957A (ja) | 組織の修復あるいは再生に用いる組織工学装置 | |
CA2450720A1 (en) | In vivo bioreactors | |
CN1713861A (zh) | 血管化增强的移植构造物 | |
Suuronen et al. | Building in vitro models of organs | |
Bücheler et al. | Tissue engineering in otorhinolaryngology | |
CN111450319A (zh) | 一种仿生的预脉管化材料及其制备方法和应用 | |
JP2024125426A (ja) | 心臓オルガノイド培養及び移植のための脱細胞心臓組織由来支持体及びその製造方法 | |
JP2023501925A (ja) | 筋線維断片を利用した回旋腱板療法 | |
CN1990054A (zh) | 一种体外诱导人骨髓基质干细胞构建软骨的方法 | |
CN111868226A (zh) | 神经细胞培养材料及神经损伤治疗剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170208 Address after: Twelfth Avenue South, Bermingham, Alabama, USA, No. 1601 Patentee after: VEO Biological Science Co.,Ltd. Address before: alabama Patentee before: The UAB Research Foundation |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170524 Address after: Virginia Patentee after: LIFENET HEALTH Address before: Twelfth Avenue South, Bermingham, Alabama, USA, No. 1601 Patentee before: VEO Biological Science Co.,Ltd. |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20080820 |